Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

NCT05993299 is registered in ClinicalTrials.gov with USWM, LLC (dba US WorldMeds) as lead sponsor.

NCT NCT05993299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Lead sponsor
USWM, LLC (dba US WorldMeds)
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2019
Completion date
March 17, 2026
Enrollment
7 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms